Association between cholesterol, high-density lipoprotein, and glucose index and risks of cardiovascular and all-cause mortality in patients with calcific aortic valve stenosis: the ARISTOTLE cohort study

胆固醇、高密度脂蛋白和葡萄糖指数与钙化性主动脉瓣狭窄患者心血管疾病和全因死亡风险之间的关联:ARISTOTLE队列研究

阅读:2

Abstract

BACKGROUND: Cholesterol, high-density lipoprotein, and glucose (CHG) index, an alternative marker of insulin resistance (IR), play a significant role in predicting cardiovascular diseases. However, its prognostic value in patients with calcific aortic valve stenosis (CAVS) remains unclear. METHODS: This study included 1175 patients diagnosed with calcific aortic valve stenosis via echocardiography from the First Affiliated Hospital of Sun Yat-sen University. Participants were grouped based on the cut-off value of the CHG index. The association between the CHG index and cardiovascular mortality and all-cause mortality in patients with calcific aortic valve stenosis was evaluated using Cox proportional hazards regression and restricted cubic model spline. RESULTS: Among the 1175 patients (mean age 68.91 ± 11.68 years, 56.6% male), the median follow-up time was 3.23 [1.15, 6.07] years. In the fully adjusted model, each 1-unit increase in the CHG index was linked to a 53% higher risk of cardiovascular mortality and a 43% higher risk of all-cause mortality. Moreover, compared to the low CHG index group, the high CHG index group had a 1.44-fold higher risk of cardiovascular mortality and a 1.43-fold higher risk of all-cause mortality. The restricted cubic spline model indicated a linear relationship between the CHG index and the risks of cardiovascular mortality (p for nonlinearity = 0.529) and all-cause mortality (p for nonlinearity = 0.436). CONCLUSION: Higher levels of insulin resistance, as assessed by the CHG index, are associated with increased risks of cardiovascular and all-cause mortality in patients with calcific aortic valve stenosis. TRIAL REGISTRATION: RISk facTOr assessmenT and prognosis modeL construction (ARISTOTLE) study (Registry: ClinicalTrials.gov, TRN: NCT06069232, Registration date: 1 October 2023).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。